Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  IntegraGen    ALINT   FR0010908723

INTEGRAGEN

(ALINT)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

IntegraGen : Announces Publication of of miR-31-3p Data in Clinical Cancer Research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/04/2018 | 02:32am EST

IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled 'Validation of miR-31-3p Expression Level to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer' was published online in Clinical Cancer Research, a leading oncology journal which focuses on innovative clinical and translational cancer research studies that bridge the laboratory and the clinic.

Click here to view press release

Disclaimer

IntegraGen SA published this content on 04 September 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 04 September 2018 06:31:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INTEGRAGEN
09/23INTEGRAGEN : Half-year results
CO
06/30INTEGRAGEN : Press release on General Assembly voting results
PU
03/05INTEGRAGEN : and Advanced Biological Laboratories Sign Global Licensing Agreemen..
AQ
2018INTEGRAGEN : Half-year results
CO
2018INTEGRAGEN : Announces Publication of of miR-31-3p Data in Clinical Cancer Resea..
PU
2018INTEGRAGEN : Announces Publication of Data Which Demonstrates the Ability of miR..
BU
2018INTEGRAGEN : Monthly statement on outstanding equity shares and voting rights
CO
2018INTEGRAGEN : The SeqOIA Cooperative Health Group Selects IntegraGen As the Opera..
BU
2018INTEGRAGEN ACHIEVES ISO 13485 : 2016 Certification for the Design, Manufacturing..
BU
2018INTEGRAGEN : Presents Data from Liquid Biopsy Studies of Proprietary miRNAs duri..
PU
More news
Financials (EUR)
Sales 2019 9,80 M
EBIT 2019 -0,20 M
Net income 2019 -0,20 M
Finance 2019 2,20 M
Yield 2019 -
P/E ratio 2019 -32,0x
P/E ratio 2020 -
EV / Sales2019 0,41x
EV / Sales2020 0,42x
Capitalization 6,21 M
Chart INTEGRAGEN
Duration : Period :
IntegraGen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTEGRAGEN
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 4,15  €
Last Close Price 0,96  €
Spread / Highest target 332%
Spread / Average Target 332%
Spread / Lowest Target 332%
EPS Revisions
Managers
NameTitle
Bernard Courtieu Chairman & Chief Executive Officer
Laurence Riot Lamotte Chief Financial Officer
Gerald D. Wagner Director
Peter Behner Director
Yannick Sabatin Director
Sector and Competitors
1st jan.Capitalization (M$)
INTEGRAGEN-13.51%7
GUARDANT HEALTH, INC.95.11%6 887
GENSCRIPT BIOTECH CORPORATION81.33%4 552
IOVANCE BIOTHERAPEUTICS, INC.189.15%3 229
INVITAE CORPORATION60.22%1 710
VERACYTE, INC.130.29%1 415